Are there socioeconomic disparities in women having discussions on human papillomavirus vaccine with health care providers? by unknown
Wong and Do BMC Women's Health 2012, 12:33
http://www.biomedcentral.com/1472-6874/12/33RESEARCH ARTICLE Open AccessAre there socioeconomic disparities in women
having discussions on human papillomavirus
vaccine with health care providers?
Ker Yi Wong and Young Kyung Do*Abstract
Background: Human papillomavirus (HPV) vaccine recommendation by a health care provider (HCP) is an
important predictor of vaccine receipt. We examined whether being of a minority race/ethnicity, having lower
income and education, and the lack of health insurance and a regular HCP are each associated with a lower
likelihood of a discussion on HPV vaccine occurring between a woman and her HCP.
Methods: A sample of 1,631 women aged 18 years and older was drawn from the 2007 Health Information
National Trends Survey. Given that only a subgroup of women who were aware of the HPV vaccine were asked if
they had a discussion with their HCPs, we estimated a probit model correcting for sample selection.
Results: Among those aware of the HPV vaccine, 17.3% of respondents reported having discussions on the vaccine
with their HCPs. Compared with Whites, African Americans were less likely to be aware of the HPV vaccine but
more likely to have discussions with their HCPs concerning the vaccine. A statistically significant association
between lower income and education levels and a lower likelihood of HPV vaccine awareness was observed, but
low levels of income and education did not appear to affect the probability of having HPV vaccine discussions
with HCPs.
Conclusions: Socioeconomically disadvantaged women did not show a lower propensity to have vaccine
discussions with their HCPs, suggesting that HCPs can be a major catalyst in increasing vaccine receipt among the
higher risk group. The results of the study suggest a two-pronged approach that seeks to raise vaccine awareness
among socioeconomically disadvantaged women at the population level and encourages HCPs to intensify
discussions about the HPV vaccine with patients.Background
Women at high risk of cervical cancer in the United
States tend to have less income, less education, and are
likely to belong to racial/ethnic minorities, namely Afri-
can Americans, Hispanics, and Asians [1-4]. This popu-
lation also bears the highest prevalence of human
papillomavirus (HPV) infection [5,6], which accounts for
99% of all cervical cancers [7]; thus, less educated and
lower income minority women would likely benefit the
most from receiving the HPV vaccine. Unfortunately,
HPV vaccination rates among this group are low, and
African Americans and Asians are less likely than* Correspondence: young.do@duke-nus.edu.sg
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reproduction in any medium, provided the orWhites to be vaccinated against HPV [8]. Low income
levels and lack of medical insurance are also associated
with lower rates of HPV vaccine initiations [9,10].
The unequal adoption of HPV vaccination can exacer-
bate the socioeconomic disparities in cervical cancer
rates. Many studies have identified predictors of HPV
vaccine uptake to address this disparity; most have found
HPV vaccine recommendation from a health care
provider (HCP) to be an important predictor of vaccine
receipt [11-21], both for adult women and for parents
considering having their daughters vaccinated. The
weight that the public places on vaccine recommenda-
tions from HCPs has prompted researchers to suggest
that HCPs can help to increase the HPV vaccine uptake
rate in the aforementioned population by educating their
patients about the vaccine.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wong and Do BMC Women's Health 2012, 12:33 Page 2 of 7
http://www.biomedcentral.com/1472-6874/12/33Despite the potentially important implications for both
clinical and public health practice, research regarding
HPV vaccine discussions between patients and their
HCPs is currently lacking. This study aimed to identify
socioeconomic factors associated with having a patient-
or HCP-initiated discussion about the HPV vaccine
among a nationally representative sample of American
women. As women of lower socioeconomic status are
less likely to have adequate access to health care, we
postulated that interaction with HCPs follows the same
disparate trajectory. Specifically, we hypothesized that
being in a minority race/ethnicity, having lower income
and education, and the lack of health insurance and a
regular HCP are each associated with a lower likelihood
of a discussion on HPV vaccine occurring between a
woman and her HCP.
Methods
Data and sample
The data for this study were drawn from the National
Cancer Institute’s 2007 Health Information National
Trends Survey (HINTS). The HINTS routinely collects
nationally representative data on the US public’s use of
and access to cancer-related information, health com-
munication trends and practices, and the public’s per-
ceptions of health risks. HINTS respondents were
recruited via two modes: (1) random digit dialing of tele-
phone numbers for recruiting respondents in computer-
assisted telephone interviews (CATI) and (2) using mail
surveys from a national listing of addresses available
from the United States Postal Service. Response rates
for the CATI and mail surveys were 24.2% and 31.0%,
respectively. Detailed information on the HINTS survey
methods can be found elsewhere [22]. Because only
CATI included the question that assessed the outcome
of interest, this analysis focused on a sub-sample of
women recruited for CATI: those who were at least
18 years of age. After excluding observations with miss-
ing data, our sample size was 1,631 individuals.
Outcome variable
The outcome of interest was a binary indicator variable
derived from the question, “Has a health care provider
such as a doctor or nurse ever talked to you about a cer-
vical cancer vaccine or HPV shot?” This question did
not differentiate between a respondent-initiated and a
HCP-initiated discussion. Only the respondents who
reported having heard of the cervical cancer vaccine or
HPV shot before taking part in the survey were asked
this question.
Explanatory variables
This study used socioeconomic and demographic charac-
teristics as explanatory variables. These variables includedhousehold income (<$20,000; $20,000 to <$50,000;
$50,000 to <$75,000; and ≥$75,000), education (some high
school, high school graduate, some college and college
graduate), race/ethnicity (White, African American, His-
panic, and other), and age group (18–34, 35–39, 40–44,
and 45 years and above), as well as any health care cover-
age, and any regular HCP. Health care coverage in the
HINTS 2007 referred to health insurance, prepaid plans
such as health maintenance organizations (HMOs), and
government plans such as Medicare. Likewise, HINTS
2007 defined a HCP as a doctor, nurse or other health
professional but not a psychiatrist or other mental health
professional. For two of these variables – any health care
coverage and any regular HCP – responses of ‘yes’ were
coded ‘1’ while responses of ‘no’ were coded ‘0’.
Statistical analysis
In this study, only women who reported being aware of
the HPV vaccine were asked to answer the question
on having any discussions with their HCPs about the
vaccine. However, HPV vaccine awareness may favor
women with more advantageous socioeconomic charac-
teristics. Thus, in terms of having discussions on HPV
vaccine with a HCP, a statistical model that only includes
respondents who were aware of the vaccine may result
in sample selection bias. This issue compromises the
study’s internal validity resulting in an underestimation
or overestimation of the effect of socioeconomic factors
on the likelihood of patients having a discussion on
HPV vaccine with their HCPs. External validity is like-
wise compromised because estimates from the sample
selected are not generalizable to the population.
To address sample selection bias, we used the heck-
prob command in Stata (version 11.0, StataCorp LP),
which simultaneously estimates the main probit model
of HPV vaccine discussion and the selection model of
being aware of the HPV vaccine, while correcting for the
potential sample selection bias [23,24].
Main probit model : Discuss ¼ Xβ1 þ E1
Discuss ¼ 1 if Discuss
 ≥ 0
0 if Discuss < 0

where Discuss* is a latent variable measuring the pro-
pensity of a vaccine discussion occurring between a
respondent and her HCP and Discuss is a dichotomous
variable indicating whether or not an HPV vaccine dis-
cussion has occurred between a respondent and her
HCP. X and β1 refer to the matrix of explanatory vari-
ables and corresponding coefficients, respectively; E1 is
the error term. A positive coefficient in β1 indicates that
the propensity of a woman to have a discussion on the
HPV vaccine with her HCP increases with a higher value
in the corresponding variable. Discuss is only observed
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(Aware = 1).
Selection model : Aware ¼ Xβ2 þ E2
Aware ¼ 1 if Aware
 ≥ 0
0 if Aware < 0

where Aware* is a latent variable measuring the propen-
sity of being aware of the HPV vaccine and Aware is
a dichotomous variable indicating whether or not a
respondent is aware of the HPV vaccine. X and β2
respectively denote the same matrix of explanatory
variables and corresponding coefficients, and E2 is the
error term. A negative coefficient in β2 indicates that
the propensity of a woman to be aware of the HPV
vaccine decreases with a higher value in the correspond-
ing variable.
Our model used the correlation coefficient (ρ) between
E1 and E2 to test for sample selection bias. A p<0.05 cut-
off was used to determine statistical significance for all
analyses. Data were weighted to adjust for survey design.
Results
Descriptive statistics
Demographic and socioeconomic characteristics of the
study sample are shown in Table 1. The majority of
respondents were White, had completed at least high
school, and had health care coverage and a regular HCP.
The sample was fairly diverse with regard to house-
hold income. Among those who were aware of the HPV
vaccine, 17.3% reported having had a discussion about
the HPV vaccine with their HCPs. The percentages of
respondents who had HPV vaccine discussions with
their HCPs did not show discernible trends with increas-
ing household income or education levels. The group
with the highest percentage of respondents who
reported having had HPV vaccine discussions with
their HCPs were African Americans (26.6%), followed by
Hispanics (17.2%), Whites (15.8%) and other (13.7%).
Among 81.5% of the respondents who were aware of the
HPV vaccine, Whites had the highest percentage of vac-
cine awareness (88.7%), followed by African Americans
(73.2%), other (66.6%), and lastly, Hispanics (58.8%).
The percentage of respondents who were aware of the
HPV vaccine was higher among respondents with higher
household income than those from lower income groups
(92.4% versus 55.3%). Similarly, HPV vaccine awareness
was higher among respondents with higher (versus
lower) education levels (89.7% versus 47.1%).
Probit model of HPV vaccine discussion with HCP, with
correction for sample selection
Results of the probit model analysis of HPV vaccine
discussions with HCPs (Table 2) showed that AfricanAmerican women (coefficient 0.515, p<0.05) were more
likely than White women to report having such discus-
sions. On the other hand, women aged 45 years and
above (coefficient −0.386, p<0.05) were less likely to have
discussions on HPV vaccine with their HCPs than
women in the reference age group of 18–34 years.
The level of household income and education, as well as
having insurance and a regular HCP did not show statis-
tically significant associations with patients having dis-
cussions on HPV vaccine with their HCPs.
Analysis of the selection model revealed that – com-
pared with the reference group (i.e., 18–34 years old,
White, household income above $75,000, college gradu-
ates) – women aged 45 years and above, belonging to an
ethnic minority group, with household income below
$50,000 or with education levels lower than or equiva-
lent to high school were less likely to be aware of the
HPV vaccine.
The statistically significant correlation coefficient of
the probit model (−0.845, p<0.01, Table 2) suggested that
the model would suffer from sample selection bias if the
study sample only consisted of respondents who were
aware of the HPV vaccine. In other words, unexplained
factors (ε2) in the model of awareness of HPV vaccine
were correlated with unexplained factors (ε1) that pre-
dict discussion with HCPs. The negative sign indicates
that ε1 and ε2 are negatively correlated.
Discussion
The primary goal of this study was to examine socioeco-
nomic differences in the likelihood of a discussion on
HPV vaccine occurring between a woman and her HCP
using a model that accounts for potential sample selec-
tion bias. Our analysis suggested that African American
women were more likely to have had discussions about
the HPV vaccine with their HCPs than White women.
Overall, we did not find evidence that socioeconomic
disadvantages were associated with a lower chance of
having a discussion on HPV vaccine with HCPs. A simi-
lar finding was reported by Hughes et al. (2009), who
did not find evident socioeconomic disparities in the
odds of reporting HCPs as previous sources of HPV vac-
cine information [25].
These results are encouraging although not intuitively
predictable. Many studies demonstrate that the socioe-
conomically disadvantaged tend to have less access to
health care [26-28], which leads to the assumption that
such individuals may have fewer opportunities to discuss
the HPV vaccine with their HCPs, supposing they have
one. However, our results contradict this assumption;
the influence of a patient’s race and socioeconomic
status on the screening practices of HCPs could primar-
ily explain this contradiction. Studies have shown that
HCPs are more likely to provide counseling services on
Table 1 Summary statistics of study sample
Whole sample Selection indicator: Main outcome:
Aware of HPV vaccine Discussed with HCP on HPV vaccine
N Column % N positive Row % N positive Row %
Overall 1631 1314 81.5 161 17.3
Age group
18–34 236 30.7 204 86.4 52 26.0
35–49 108 10.1 98 86.6 16 16.5
40–44 116 10.0 98 81.9 24 29.6
45 and above 1171 49.2 914 77.3 69 8.7
Race/ethnicity
White 1282 66.9 1084 88.7 117 15.8
African American 127 14.9 90 73.2 19 26.6
Hispanic 133 11.9 78 58.8 13 17.2
Other 89 6.3 62 66.6 12 13.7
Household income
$75,000 or more 492 30.0 453 92.4 75 21.0
$50,000 to <$75,000 303 18.9 259 89.2 24 15.9
$20,000 to <$50,000 537 34.6 434 80.3 44 14.3
<$20,000 299 16.5 168 55.3 18 17.5
Education
College graduate 613 27.9 549 89.7 72 18.1
Some college 475 33.0 407 90.0 51 17.8
High school graduate 407 27.3 301 77.6 30 14.6
Less than high school 136 11.8 57 47.1 8 20.8
Has any insurance
No 160 14.2 106 64.0 17 14.7
Yes 1471 85.8 1208 84.4 144 17.6
Has any regular HCP
No 251 21.4 178 73.0 24 14.8
Yes 1380 78.6 1136 83.8 137 17.9
All frequencies are unweighted and all percentages are weighted. HPV=human papillomavirus; HCP=health care provider.
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to a patient from a minority ethnic group and a lower
socioeconomic status than one from a non-minority eth-
nic group [29] and a higher socioeconomic status [30],
respectively. HCPs generally prioritize their screening
practices based on actual epidemiological data, showing
the association of race and socioeconomic status with
STIs [31]. Since HPV infection is a STI, a similar reason-
ing can be used to explain the lack of socioeconomic
disparities observed in this study. A HCP who is aware
that the prevalence of HPV infections is higher among
African American women and women with low levels of
education and income will be more likely to discuss the
HPV vaccine with these groups.
Secondly, both the psychosocial factors that affect a
woman’s behavior on seeking health information and thepredictors of a HCP recommending the HPV vaccine
influence whether a woman discusses the HPV vaccine
with her HCP. Individual psychosocial factors such as hav-
ing a higher internal locus of control [32,33] and a prefer-
ence for involvement in health-related decision making
[34] were found to contribute positively to information
seeking behavior. Trust in HCPs was also correlated with
more information seeking from HCPs [35]. Among HCPs,
an early adopter of a new intervention generally has a
higher intention of recommending the HPV vaccine
[36,37]. Physicians’ practices [38,39] and their beliefs and
attitudes towards the HPV vaccine [37,40] were also found
to affect their propensity to recommend the HPV vaccines
to their patients. Albeit beyond the scope of this study, the
presence of numerous HCP- and patient-related factors,
including their intricate interaction with one another,
Table 2 Probit model of having HPV vaccine discussion with HCP, correcting for sample selectiona
Variables Selection equation: Main equation:
Aware of HPV vaccine Discussed with HCP on HPV vaccine
Coefficient (95% C.I.) Coefficient (95% C.I.)
Age group
18–34 Reference Reference
35–39 0.119 (−0.385, 0.623) −0.290 (−0.638, 0.059)
40–44 −0.373 (−0.868, 0.122) 0.178 (−0.182, 0.538)
45 and above −0.630** (−1.024,–0.235) −0.386* (−0.726,–0.045)
Race/ethnicity
White Reference Reference
African American −0.505** (−0.859,–0.152) 0.515* (0.114, 0.917)
Hispanic −0.745** (−1.147,–0.343) 0.233 (−0.182, 0.649)
Other −1.028** (−1.550,–0.506) 0.369 (−0.148, 0.885)
Household income
$75,000 or more Reference Reference
$50,000 to <$75,000 −0.278 (−0.605, 0.050) −0.132 (−0.455, 0.191)
$20,000 to <$50,000 −0.360* (−0.634,–0.086) −0.158 (−0.519, 0.202)
<$20,000 −0.839** (−1.125,–0.552) 0.199 (−0.135, 0.533)
Education
College graduate Reference Reference
Some college 0.197 (−0.079, 0.474) −0.063 (−0.345, 0.220)
High school graduate −0.279* (−0.534,–0.024) 0.026 (−0.326, 0.377)
Less than high school −0.743** (−1.139,–0.347) 0.471 (−0.006, 0.947)
Has any insurance
No Reference Reference
Yes 0.152 (−0.249, 0.553) −0.088 (−0.624, 0.447)
Has any regular HCP
No Reference Reference
Yes 0.200 (−0.083, 0.482) 0.114 (−0.260, 0.488)
Constant 1.800** (1.255, 2.346) −0.563 (−1.175, 0.049)
Correlation (ρ) −0.845 ** (−0.969, –0.387)
aSample size=1,631; HPV=human papillomavirus; HCP=health care provider; *p<0.05, **p<0.01.
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discussions on HPV vaccine with HCPs.
However, similar to other studies [9,25,26,41,42], our
statistical analysis has revealed a troubling disparity in
HPV vaccine awareness across multiple dimensions of
socioeconomic status. Belonging to a minority race/
ethnicity, and having a lower household income and
education level were independently associated with a
lower probability of being aware of the HPV vaccine.
The disparities in HPV vaccine awareness were all statis-
tically significant and showed a fairly consistent gradient
for both income and education.
The results of this study have a number of important
implications for research, practice and policy. In terms
of research, our statistical approach provides a fullerpicture of socioeconomic disparities in HPV vaccine by
simultaneously examining two related indicators. How-
ever, the eventual uptake of the vaccine depends on a
complex interplay of factors in a woman’s psychosocial
milieu as well as other demographic and socioeconomic
factors. Thus, future research that assesses the impact of
socioeconomic status on the integrated continuum of
HPV vaccine awareness, acquisition of information, and
vaccine uptake will greatly inform policy makers and
health care providers in guiding education and practice.
Regarding the implications for clinical practice, HCPs
may be the preferred source of health care information
for the socioeconomically disadvantaged because of the
lack of other reliable options; this preference results in a
higher likelihood of having discussions on HPV vaccine.
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ate, objective information about the vaccine, and help
dispel any myths or negative attitudes about HPV vaccin-
ation, thereby allowing socioeconomically disadvantaged
women to make informed decisions for themselves and
for their daughters.
Lastly, our findings that lower socioeconomic status is
associated with lower awareness but not with lower
opportunities for discussions on HPV vaccine with HCPs
has important public health and policy implications.
Primarily, social disparities in HPV vaccine uptake will
be greatly reduced if discussions between patients and
their HCPs become more prevalent. Targeted outreach
programs should also be promoted in order to raise
awareness about the vaccine among socioeconomically
disadvantaged women and should be tailored to address
attitudes and perceptions that are specific to each ethnic
group. In addition, given the potential for HCPs to
ameliorate social disparities in HPV vaccine uptake and
its importance, public health efforts can be directed
toward giving full support to HCPs for HPV vaccination
promotion. This support can come in the form of
informative pamphlets in various vernaculars to enhance
communication and provide easily accessible, timely,
and up-to-date information on HPV vaccine research.
Notwithstanding these implications, the findings pre-
sented herein should be considered in the context of a
few limitations. A key limitation of this study was the
short interval between the FDA approval of the quadri-
valent HPV vaccine in 2006 and the launch of the
HINTS in early 2008. Thus, the small number of respon-
dents who reported having HPV vaccine discussions
with their HCPs may not be reflective of the correspond-
ing number today. Future research involving HCPs who
are more familiar with the vaccines may offer a more
accurate picture of the prevalence of vaccine discussions
between women and their HCPs. A second limitation,
which is related to the first, is that four years have
elapsed since the launch of HINTS in early 2008; thus,
the results may not reflect the current situation today.
However, while average awareness of the vaccine may
have increased over the years, the increment of increase
is unknown and its rate differs among populations.
Hence, this study is still pertinent in underserved popu-
lations whose awareness of the HPV vaccine and accessi-
bility to HCPs remains low, and in which identifying
ways to best target patient education remains crucial.
Additionally, the self-reported status of having discus-
sions on HPV vaccine with a HCP is subject to recall
bias. Moreover, the content and extent of the discuss-
ion was unknown, and a standard definition for what
qualifies as a “discussion on HPV vaccine” was not
described in the survey. This could have resulted in an
underestimation or overestimation of the number ofrespondents who reported having discussions on HPV
vaccine with their providers. Lastly, the HINTS was
not developed to include constructs that aim to capture
HCP factors and individual psychosocial factors that
could have influenced the likelihood of women having
discussions on HPV vaccine with their HCPs. Future
research surveys designed to capture all of these factors
could give a more comprehensive analysis of socioeco-
nomic disparities in HPV vaccine discussions.
Conclusions
Numerous studies have demonstrated that socioecono-
mically disadvantaged women are at higher risk of HPV-
related mortality and morbidity. However, the compar-
able tendencies to have discussions on HPV vaccine with
HCPs amongst women across different socioeconomic
groups differed from the wide disparities in awareness
found in our study, suggesting that HCP involvement in
broader public health efforts is of paramount importance
in reducing socioeconomic disparities in HPV infection
and cervical cancer.
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